|
Tuesday, 31 January 2012 18:52 |
|
YOKNEAM, ISRAEL--Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that it will release fourth quarter 2011 financial results before the market opens on Thursday, February 9, 2012.
|
|
Read more...
|
|
Tuesday, 31 January 2012 18:50 |
|
SHANGRI-LA COUNTY, CHINA--Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that it has signed a Letter of Intent ("LOI") to cooperate with Anhui Taihe Pharmaceutical Group Co., Ltd. ("Anhui Taihe Pharmaceutical Group"), a wholesale pharmaceutical distribution company based in Anhui province with a network across 16 provinces and municipalities in China.
|
|
Read more...
|
|
Tuesday, 15 November 2011 21:57 |
|
CALGARY, AB --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics”) today announced that interim results from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
|
|
Read more...
|
|
Monday, 14 November 2011 21:06 |
|
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB.PK) (Pinksheets: KBLB.PK) (the “Company” or "Kraig") announced that researchers at the University of Notre Dame, utilizing customized zinc finger configurations licensed to Kraig from Sigma-Aldrich, succeeded in creating seven or more strains of transgenically modified silkworms.
|
|
Read more...
|
|
Monday, 14 November 2011 20:51 |
|
FISHERS, Ind.--Positron Corporation (OTCBB:POSC.OB - News), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce today that on Friday November 11, 2011, Positron and Manhattan Isotope Technology LLC. (MIT LLC) entered into a binding Letter of Intent to acquire MIT LLC. The transaction will close January 2, 2012 upon execution of final transaction documents.
|
|
Read more...
|
|
Thursday, 03 November 2011 19:00 |
|
DÜSSELDORF, GERMANY - ImmunAid Pty. Ltd. has been awarded a European patent for its pioneering work in the treatment of cancer, based on monitoring the immune cycle of each individual patient and then determining the optimal time to deliver treatment to that patient.
|
|
Read more...
|
|
Monday, 02 May 2011 10:37 |
|
ANNAPOLIS, Md. -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that closing arguments in its breach of contract action against SIGA Technologies were held on Friday, April 29, 2011 in the Delaware Court of Chancery. Post trial briefs in the case were submitted by both parties to the Court in April 2011.
|
|
Read more...
|
|
Saturday, 20 March 2010 00:04 |
|
SAN DIEGO-- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced the presentation of a 2,000 patient meta-analysis examining patient response to antiplatelet therapy after percutaneous coronary intervention (PCI).
|
|
Read more...
|
|
Thursday, 18 February 2010 13:38 |
|
Don't forget to sign up for instant phone alerts!
|
|
Wednesday, 09 September 2009 03:00 |
 What a line up. Bristol-Myers Squibb, GlaxoSmithKline, Schering-Plough, Pfizer, Wyeth, Celgene, Cephalon and King. With nine pharmaceutical agreements and more than 20 molecules in various stages of development Ligand epitomizes the term "Multiple Shots on Goal".
With all these catalysts I am looking for shares of Ligand to move back to 2007 levels in the very near future.
|
|
Read more...
|
|
|
